Bluebird’s Fast Lyfgenia Launch Was A Year And A Half In The Making
Zynteglo Build Gives Firm A Leg Up In Sickle Cell Disease
The company said when Zynteglo was approved for beta-thalassemia that its launch would lay the groundwork for its sickle cell gene therapy Lyfgenia, and the strategy is paying off so far with a fast ramp-up.
